News

April 20, 2018

Patients with Peripheral T-cell Lymphoma Resistant to First-Line Therapy Show Worse Outcomes, Study Finds

News

Patients with peripheral T-cell lymphomas receiving standard treatment have worse outcomes if they are not responsive to first-line therapy, a prospective study shows. Bone marrow transplants undertaken after these therapies have ... Read more

April 19, 2018

LLS Launches Online Video on How to Join Clinical Trials, What to Expect

News

The Leukemia & Lymphoma Society (LLS) launched a free video education program for patients and caregivers to help explain the process of joining a clinical trial and what to expect when ... Read more

April 18, 2018

Humalutin Inhibits Tumor Growth in Non-Hodgkin’s Lymphoma, Preclinical Study Shows

News

Humalutin (177Lu-NNV003), a novel tumor-targeting antibody labeled with radiation, demonstrated promising results in animal models of non-Hodgkin’s lymphoma (NHL), Nordic Nanovector announced. Humalutin is an investigational, humanized version of Betalutin — Nordic’s lead therapy candidate ... Read more

April 17, 2018

New DLBCL Genetic Subtypes Offer Potential for Tailored Therapies, Researchers Say

News

An analysis of the genomic alterations and gene activity of diffuse large B-cell lymphoma (DLBCL) samples has allowed researchers to identify four genetic subtypes of the disease, which could help ... Read more

April 16, 2018

Blocking a MicroRNA Improves Symptoms of Chronic Graft-versus-Host Disease in Mouse Model

News

Blocking a specific microRNA molecule reduced symptoms of graft-versus-host disease (GVHD) in mouse models of bone marrow transplants, a study shows. Findings from this research, led by investigators at the ... Read more

April 13, 2018April 13, 2018

Hepatitis B Infection Increases Risk of Non-Hodgkin’s Lymphoma, Research Shows

News

Chronic infection with the hepatitis B virus (HBV) is associated with a significantly higher risk of non-Hodgkin’s lymphoma, particularly for diffuse large B-cell lymphoma and follicular lymphoma, a new study revealed. ... Read more

April 12, 2018June 22, 2018

FDA Grants Priority Review to Duvelisib for Two Lymphoma Types

News

The U.S. Food and Drug Administration (FDA) will review an application requesting duvelisib’s full approval for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for ... Read more

April 11, 2018

Tenalisib Receives FDA Orphan Drug Status for Treatment of Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration has granted orphan drug status to investigational therapy tenalisib (RP6530) for the treatment of cutaneous T-cell lymphoma, Rhizen Pharmaceuticals announced. In December, the therapy also received orphan ... Read more

April 10, 2018April 10, 2018

Phase 2b Trial of Betalutin in Relapsed Follicular Lymphoma Patients on Track, Nordic Says

News

A Phase 2b trial evaluating Betalutin — a tumor-targeting antibody labeled with a type of radiation — as a third-line therapy for follicular lymphoma patients will conclude a little later than ... Read more

April 9, 2018

First Patient Dosed in Phase 3 Trial of Denovo’s DB102 Plus Chemo for High-risk DLBCL

News

A pivotal Phase 3 trial evaluating Denovo Biopharma‘s investigational therapy DB102 (enzastaurin) as an add-on to standard chemotherapy for high-risk diffuse large B-cell lymphoma (DLBCL) has started dosing patients. The ENGINE ... Read more